NCT00364091

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 365 (actual)
• Sponsor: Vistakon Pharmaceuticals · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

Conditions

• Allergic Conjunctivitis

Interventions

Type	Name	Description
DRUG	R89674 0.025% ophthalmic solution

Timeline

• Start date: 2006-08-01
• Primary completion: 2006-10-01
• First posted: 2006-08-15
• Last updated: 2011-09-27

Locations

6 sites across 1 country: United States